Related Experiment Videos

Lipid lowering to delay the progression of coronary artery disease

Michael D Feher¹

¹Lipid Clinic, Beta Cell Diabetes Centre, Chelsea & Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. michael.feher@chelwest.nhs.uk

Heart (British Cardiac Society)

|March 18, 2003

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Combining Sodium-Glucose Co-Transporter-2 Inhibitor Plus Glucagon-Like Peptide-1 Receptor Agonist for Glucose-Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real-World Clinical Practice (CombiKid Study).

Diabetes, obesity & metabolism·2026

A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2024

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study.

EClinicalMedicine·2024

Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies.

Diabetes, obesity & metabolism·2023

Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.

Diabetes, obesity & metabolism·2022

Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.

Cardiovascular diabetology·2021

See all related articles